Article
Systems analysis uncovers early temozolomide responses and peptide antigens in glioblastoma
2025-11-12
Abstract excerpt
Temozolomide (TMZ) is the standard treatment for nearly all glioblastoma (GBM) patients, as it is the only chemotherapy shown to extend overall survival. However, this benefit is limited to a few months, underscoring the need for combination strategies to improve its efficacy. While TMZ-induced DNA damage can both mediate cytotoxicity and promote resistance, DNA damage more broadly can also stimulate immune activa...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 93f68f83-1271-5193-86b2-a0b007545eac
- DOI
- 10.1101/2025.11.10.687735
